ArticleJournal of biopharmaceutical statistics2018
A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Mourad Tighiouart et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this papercites it